PD-L1 Inhibitor Avelumab May Improve Survival in Metastatic Urothelial Carcinoma
Urothelial carcinoma, the most common subtype of bladder cancer, presents a host of treatment challenges, says Andrea B. Apolo, MD, a medical oncologist at the National Cancer Institute (NCI) and chief of the Bladder Sancer Section of the NCI's ...
OncLive - Wed, 07 Oct 2015 06:18

Avelumab Receives Fast-Track for Merkel Cell Carcinoma
A new PD-L1 inhibitor being developed by Pfizer and Merck has been placed on the Fast Track by the FDA. Avelumab is a fully humanized anti-PD-L1 monoclonal antibody being developed for metastatic Merkel cell carcinoma (MCC), an aggressive form of ...
AJMC.com Managed Markets Network - Wed, 07 Oct 2015 08:22

FDA grants avelumab fast track designation for metastatic Merkel cell carcinoma
Healio - Wed, 07 Oct 2015 07:48

Pfizer (PFE), Merck KGaA Announce Receipt of FDA Fast-Track Designation for ...
StreetInsider.com - Wed, 07 Oct 2015 04:03

Pfizer drug gets fast-track status
theday.com - Wed, 07 Oct 2015 08:45

Merck KGaA, Pfizer Announce Fast Track Designation For Avelumab
Nasdaq - Wed, 07 Oct 2015 03:52

Merck KGaA and Pfizer get their fifth-place immunotherapy on the FDA fast track
FierceBiotech - Wed, 07 Oct 2015 08:00

Merck and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA ...
Business Wire India (press release) - Wed, 07 Oct 2015 05:22

Bristol-Myers Squibb's Opdivo (nivolumab) Demonstrates Superior Renal Cell ...
Bristol-Myers Squibb Company announced results from CheckMate -025, a Phase 3 clinical study comparing BMS's drug Opdivo (nivolumab) to everolimus in advanced renal cell carcinoma (RCC) after prior anti-angiogenic treatment. The CheckMate study ...
Immuno-Oncology News - Tue, 06 Oct 2015 05:00

Ascend Announces Patients with Nodular Basal Cell Carcinoma Receives First ...
MELBOURNE, Australia, Oct. 7, 2015 /PRNewswire/ -- Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company focused on developing innovative cancer therapeutics, today announced the first nodular Basal Cell Carcinoma patient (nBCC) ...
PR Newswire (press release) - Wed, 07 Oct 2015 06:07

Global Patterns of Hepatocellular Carcinoma Management
Background & Aims: Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life ...
Medscape - Thu, 01 Oct 2015 21:18

Drugs Show New Promise in Fighting Advanced Renal Cell Carcinoma
Renal cell carcinoma, the most common form of the disease, is often diagnosed when it has already spread to other organs — and until recently, patients had few therapeutic options. Now, two studies from MSK researchers and colleagues point to ...
Memorial Sloan Kettering Cancer Center (blog) - Mon, 28 Sep 2015 06:23

Cabozantinib Extends PFS More Than Everolimus in Renal Cell Carcinoma
Cancer Therapy Advisor - Mon, 28 Sep 2015 09:01

Nivolumab 'likely to change the treatment' of advanced renal cell carcinoma
Healio - Sat, 26 Sep 2015 07:15

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma
OncLive - Fri, 25 Sep 2015 15:18

Positive Phase 3 Results for Opdivo in Renal Cell Carcinoma
Monthly Prescribing Reference (registration) - Mon, 28 Sep 2015 12:41

Immune checkpoint inhibitor increases survival in patients with advanced renal ...
News-Medical.net - Fri, 25 Sep 2015 22:23

Nivolumab Improves Overall Survival in Patients With Advanced Renal Cell Carcinoma
Targeted Oncology - Mon, 28 Sep 2015 11:56

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ
1. In a prospective cohort study of over 1000 patients with lobular carcinoma-in-situ, the use of a chemopreventative agent was associated with a significantly reduced risk of invasive breast cancer. 2. Age of diagnosis and family history were not ...
2 Minute Medicine - Fri, 02 Oct 2015 22:03

FDA grants orphan drug designation to avelumab for Merkel cell carcinoma
“We continue to dedicate significant resources to accelerate our clinical trial program, with a goal of helping patients who are fighting rare and difficult-to-treat diseases, such as Merkel cell carcinoma,” Luciano Rossetti, MD, head of Global ...
Healio - Mon, 28 Sep 2015 12:52

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014